Transgene

Transgene Intangible Assets

The Intangible Assets of Transgene (TNG.PA) as of Oct 10, 2026 is 62,000.00 EUR. In the previous year, Intangible Assets was 80,000.00 EUR — a change of -22.50% (lower).

Intangible Assets

62,000.00EUR

YoY

-22.50%

Last updated:

Intangible Assets of Transgene is 2024 62,000.00 EUR. Intangible Assets of Transgene was 2023 80,000.00 EUR. It decreases by -22.50% lower compared to the previous year.

The Transgene Intangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Intangible Assets
Date
Intangible Assets
Jan 1, 2017
250,000.00 EUR
Jan 1, 2018
180,000.00 EUR
Jan 1, 2019
147,000.00 EUR
Jan 1, 2020
141,000.00 EUR
Jan 1, 2021
92,000.00 EUR
Jan 1, 2022
77,000.00 EUR
Jan 1, 2023
80,000.00 EUR
Jan 1, 2024
62,000.00 EUR
The Transgene Intangible Assets history
YEARIntangible AssetsYoY
62,000.00EUR-22.50%
80,000.00EUR+3.90%
77,000.00EUR-16.30%
92,000.00EUR-34.75%
141,000.00EUR-4.08%
147,000.00EUR-18.33%
180,000.00EUR-28.00%
250,000.00EUR-40.90%
423,000.00EUR-12.78%
485,000.00EUR-54.07%
1.06 MEUR—
Access this data via the Eulerpool API
Get Free API Key

Transgene Stock analysis

What does Transgene do? Transgene SA is a French biotechnology company specializing in the development and production of therapeutics, with a focus on cancer medications. It has a strong patent portfolio in the field of viral vectors, which are used for targeted gene therapy. The company's main areas of operation are clinical trials, research, and production. Transgene has research and production facilities in Strasbourg and Lyon, with over 100 employees. It has established partnerships with pharmaceutical companies, including Takeda Pharmaceuticals, for the development and marketing of therapeutics. Its flagship product, OncoVir-1®, is an immunomodulator that stimulates the immune system to fight tumor cells. Another promising product is TG4010, a therapeutic vaccine for non-small cell lung carcinoma. Transgene is an emerging company with a promising portfolio of cancer therapeutics, leveraging its expertise in viral vectors and collaborating closely with industry partners to expedite the development of marketable products. Transgene is expected to play a significant role in the development of new and innovative cancer treatments. Transgene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Transgene stock

Intangible Assets of Transgene is 62,000.00 EUR in 2024.

Intangible Assets of Transgene changed from 80,000.00 EUR to 62,000.00 EUR, representing a -22.50% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Intangible Assets Transgene since 2006 – with annual values, charts, and detailed analysis.

Intangible assets are non-physical assets such as patents, trademarks, copyrights, and software. They can be significant value drivers for technology and pharmaceutical companies.

Intangible Assets's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Intangible Assets's Transgene historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Balance Sheet — Transgene

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Transgene